Abstract 2-Oxyindole derivatives represented by the following general formula: <IMAGE> where R1 is selected from the group consisting of hydrogen, C1-4 alkyl, C2-4 alkenyl, benzyl and phenethyl; A is -CH=CH- or <IMAGE> wherein R2 or R3 may be the same or different and are selected from the group consisting of hydrogen and C1-4 alkyl; R4 is -OR5, wherein R5 is selected from the group consisting of hydrogen, C1-8 alkyl, cyclohexyl, benzyl and phenethyl, or <IMAGE> wherein R6 and R7 may be the same or different and are selected from the group consisting of hydrogen, C1-4 alkyl, benzyl, phenethyl and together with the nitrogen atom, a heterocyclic group selected from the group consisting of a piperidino, morpholino, piperazino or thiazolino group; and m and n each are zero or a positive integer with m+n being no more than 11. The 2-oxyindole derivatives have excellent effects on the inhibition of platelet aggregation.
A compound of the formula ##STR128## where R 1 is selected from the group consisting of hydrogen, C 1-4 alkyl, C 2-4 alkenyl, benzyl and phenethyl; A is --CH═CH-- or ##STR129## wherein R 2 or R 3 may be the same or different and are selected from the group consisting of hydrogen and C 1-4 alkyl; R 5 is selected from the group consisting of hydrogen, C 1-8 alkyl, cyclohexyl, benzyl and phenethyl and m and n each are zero or a positive integer with m+n being no more than 11.
Claim 2
Dependent Claim
91 words
A compound of the formula ##STR128## where R 1 is selected from the group consisting of hydrogen, C 1-4 alkyl, C 2-4 alkenyl, benzyl and phenethyl; A is --CH═CH-- or ##STR129## wherein R 2 or R 3 may be the same or different and are selected from the group consisting of hydrogen and C 1-4 alkyl; R 5 is selected from the group consisting of hydrogen, C 1-8 alkyl, cyclohexyl, benzyl and phenethyl and m and n each are zero or a positive integer with m+n being no more than 11.
Claim 3
Dependent Claim
10 words
A compound according to claim 1 wherein A is ##STR130##
Claim 4
Dependent Claim
21 words
A pharmaceutical composition for inhibiting platelet aggregation which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
56 words
A method for inhibiting platelet aggregation in the blood of a subject which comprises administering to the subject a pharmaceutical composition containing the compound of claim 1 and a pharmaceutically acceptable carrier in a dosage equivalent to about 0.1 mg. to about 100 mg. of said compound per day per kg. of weight of the subject.